14 December 2023 - Spending on biologics in 2021 represented $260 billion or 46% of all spending on prescription drugs in ...
13 November 2023 - Median brand name drug launch prices increased from $2,115 in 2008 to $180,007 in 2021. ...
13 November 2023 - In 2021, 46% ($260 billion) of all gross prescription drug spending in the US was on biologic ...
2 October 2023 - A US Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo ...
1 August 2023 - Brand name pharmaceutical manufacturers often sustain high prices in the US by obtaining patents that delay generic ...
28 January 2023 - AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. ...
25 January 2023 - As the 118th Congress convenes this month in Washington D.C., many pundits and advocates have little ...
13 January 2022 - In 2022, several bills were introduced in Congress to revamp US intellectual property law. ...
6 December 2022 - The United States on Tuesday urged delaying a decision on whether to waive patent protection for ...
4 November 2022 - The US Supreme Court on Friday agreed to hear Amgen's bid to revive patents on its ...
3 August 2022 - A U.S. appeals court on Monday affirmed that AbbVie Inc did not unlawfully block competition by ...
1 August 2022 - New drugs are protected by patents that block generic competition and allow manufacturers to charge high prices. ...
9 June 2022 - Letter asks U.S. Patent and Trademark Office to crack down on "highly similar" patents for single ...
17 May 2022 - Recent studies have examined strategic behaviours in the pharmaceutical industry that extend patent and regulatory protection, known ...
24 February 2022 - The Patent and Trademark Law Amendments Act (Bayh-Dole Act [35 USC §200-212]) was enacted in 1980 and ...